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Abstract
Purpose:  Obesity  is  a  late  effect  in  survivors  of  childhood  cancer  and  correlates  with  chronic
complications.  Survivors  of  leukemia,  brain  tumors,  and  hematopoietic  stem  cell  transplanta-
tion are  more  likely  to  develop  obesity  resulting  from  treatment  modalities  such  as  radiotherapy
and glucocorticoids.  This  paper  analyzes  and  integrates  the  current  data  available  to  health  pro-
fessionals in  order  to  clarify  strategies  that  can  be  used  to  treat  and  prevent  obesity  in  childhood
cancer survivors.
Sources:  This  is  a  literature  review  from  on  scientiﬁcally  reliable  electronic  databases.  We
selected  articles  published  in  the  last  ﬁve  years  and  earlier  articles  of  great  scientiﬁc  impor-
tance.
Data synthesis: The  mechanisms  involved  in  the  pathophysiology  of  obesity  in  cancer  sur-
vivors are  not  completely  understood,  but  it  is  believed  that  damage  to  the  hypothalamus
and endocrine  disorders  such  as  insulin  resistance,  leptin  resistance,  and  hormone  deﬁciency
may be  involved.  The  body  composition  of  this  group  includes  a  predominance  of  adipose  tissue,
especially  in  those  undergoing  hematopoietic  stem  cell  transplant  and  total  body  irradiation.
The use  of  body  mass  index  in  these  patients  may  lead  to  an  underestimation  of  individuals’
risk for  metabolic  complications.
Conclusion:  Early  identiﬁcation  of  groups  using  accurate  anthropometric  assessments,  inter-
ventional treatment,  and/or  preventative  measures  and  counseling  is  essential  to  minimize
the adverse  effects  of  treatment.  Physical  activity  and  healthy  eating  to  promote  adequacy  of
weight in  the  whole  population  should  be  encouraged.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
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A  inﬂuência  do  tratamento  antineoplásico  sobre  o  peso  de  sobreviventes  do  câncer
na  infância
Resumo
Objetivo:  A  obesidade  é  um  efeito  tardio  em  sobreviventes  do  câncer  na  infância  e  está  correla-
cionada a  complicac¸ões  crônicas.  Os  sobreviventes  da  leucemia,  tumores  cerebrais  e  transplante
de células-tronco  hematopoiéticas  têm  maior  probabilidade  de  desenvolver  obesidade  como
resultado  das  modalidades  de  tratamento,  como  radioterapia  e  glicocorticoides.  Este  artigo
analisa e  integra  os  dados  atuais  disponíveis  a  proﬁssionais  da  saúde  para  esclarecer  as  estraté-
gias que  podem  ser  utilizadas  para  tratar  e  prevenir  a  obesidade  em  sobreviventes  do  câncer
na infância.
Fontes:  Esta  é  uma  análise  da  literatura  de  bases  de  dados  eletrônicas  cientiﬁcamente  con-
ﬁáveis. Selecionamos  artigos  publicados  nos  últimos  cinco  anos  e  artigos  mais  antigos  de  grande
importância  cientíﬁca.
Resumo  dos  dados:  Os  mecanismos  envolvidos  na  ﬁsiopatologia  da  obesidade  em  sobreviventes
do câncer  não  são  completamente  entendidos,  porém  acredita-se  que  o  dano  no  hipotálamo
e disfunc¸ões  endócrinas,  como  resistência  à  insulina,  resistência  à  leptina  e  deﬁciência  hor-
monal, possam  estar  envolvidos.  A  composic¸ão  corporal  desse  grupo  inclui  uma  predominância
de tecido  adiposo,  principalmente  em  pacientes  submetidos  a  transplante  de  células-tronco
hematopoiéticas  e  irradiac¸ão  de  todo  o  corpo.  O  uso  do  índice  de  massa  corporal  nesses
pacientes  pode  subestimar  indivíduos  em  risco  de  complicac¸ões  metabólicas.
Conclusão:  A  identiﬁcac¸ão  precoce  de  grupos  por  meio  de  avaliac¸ões  antropométricas  precisas,
tratamento  intervencional  e/ou  medidas  preventivas  e  aconselhamento  é  fundamental  para
minimizar  os  efeitos  colaterais  do  tratamento.  A  atividade  física  e  alimentac¸ão  saudável  devem
ser incentivadas  para  promover  a  adequac¸ão  do  peso  na  populac¸ão  em  geral.
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este e´ um  artigo
Open Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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‘‘Childhood’’.  Articles  published  in  the  last  ﬁve  years  andntroduction
besity  is  an  acknowledged  late  effect  in  childhood  can-
er  survivors  that  is  especially  observed  in  certain  groups,
uch  as  survivors  of  brain  tumors  or  leukemia,  since  these
ancers  are  associated  with  other  chronic  diseases  including
iabetes,  hypertension,  depression,  cardiovascular  disease,
nd  dyslipidemia.1,2 Obesity  in  these  groups  of  individuals
s  well  described  in  the  literature;  among  all  survivors,  cra-
ial  radiotherapy  (CRT),  chemotherapy,  and  steroids  have
een  documented  to  contribute  to  an  alteration  in  the  body
omposition  of  patients  already  discharged  from  oncologic
reatment.3
Endocrine  and  metabolic  alterations  have  been  reported
s  highly  prevalent  in  cancer  survivors  who  have  received
 hematopoietic  stem  cell  transplant  (HSCT).  Contributing
actors  may  include  an  intense  or  prolonged  immunosup-
ressive  treatment,  post-transplant  endocrine  dysfunction,
nd  insulin  or  leptin  resistance.  Although  there  are  no
tudies  suggesting  HSCT  as  causative,  prevention  and  early
reatment  of  cardiovascular  risks  in  these  patients  might
iminish  the  incidence  of  late  complications  after  the
ransplant.4
The  early  identiﬁcation  of  high-risk  groups,  followed
y  a  treatment  plan  based  on  metabolic  and  nutritional
ssessments  that  includes  increased  physical  activity,  is  an
ssential  component  in  the  prevention  of  obesity.5 With  this
nowledge,  it  is  important  to  study  the  causes  of  obesity  in
e
w
all  survivors  of  childhood  cancer,  addressing  not  only  causes
ell  documented  in  the  literature  as  inﬂuential,  but  also  the
eldom  explored  causal  factors  in  this  group.  The  authors
lso  question  the  efﬁcacy  of  body  mass  index  (BMI)  as  an
ndicator  to  identify  patients  who  are  overweight,  since
hese  individuals  experience  changes  in  body  composition,
nd  therefore  patients  at  risk  for  metabolic  complications
ay  be  overlooked.  Thus,  the  goal  of  this  review  is  to  pro-
ote  discussion  on  the  theme  through  data  compilation  and
nderstanding  possible  causes,  and  to  alert  health  profes-
ionals  of  the  importance  of  this  topic.  Promotion  of  debate
n  the  academic  community  is  essential  to  encourage  the
mplementation  of  future  public  health  policies  to  prevent
besity  in  children  and  adolescents  with  cancer  and  in  future
urvivors.
ethods
his  is  a  literature  review  from  on  scientiﬁcally  reliable
lectronic  databases  and  conducted  in  the  second  half
f  2014  and  ﬁrst  half  2015  using  the  following  descrip-
ive  terms  related  to  the  topic:  ‘‘Obesity’’;  ‘‘Survivor’’;
‘Antineoplastic  agents/adverse  effects’’;  ‘‘Neoplasms’’;arlier  articles  of  great  scientiﬁc  importance  were  selected,
ith  exclusion  of  those  that  did  not  ﬁt  the  proposed  work,
nd  were  stratiﬁed  according  to  study  design,  number  of
Treatment  inﬂuence  on  the  weight  of  cancer  survivors  561
Table  1  Summary  of  studies  on  the  main  risk  factors  related  to  obesity  and  metabolic  syndrome  in  childhood  cancer  survivors.
Outcomes  No.  of  studies
Obesity
Risk  factor Author/Tumor  type
Cranial  radiotherapy  (CRT)  Oefﬁnger  et  al.  (2003)/Leukemia
Chow  et  al.  (2013)/Leukemia
Lustig  et  al.  (2003)/Central  nervous  system  (CNS)
Ahmet  et  al.  (2006)/CNS
Miller  et  al.  (2010)/Leukemia  and  lymphoma
5
Female  CRT  (>20  Gy) Oefﬁnger  et  al.  (2003)/Leukemia 1
Age (<5  years) Oefﬁnger  et  al.  (2003)/Leukemia 1
Age (<10  years) Chow  et  al.  (2013)/Leukemia 1
Hematopoietic  stem  cell  transplant
(HSCT)
Chow  et  al.  (2013)/Leukemia
Inaba  et  al.  (2012)/All  types
Ruble  et  al.  (2012)/All  types
3
Antineoplastic  treatment  (any  type
and  phase)
Mayer  et  al.  (2000)/Leukemia
Esbenshade  et  al.  (2011)/Leukemia
2
Overweight  (initiation  of  treatment)  Zhang  et  al.  (2014)/Leukemia  1
Overweight (regardless  of  other
characteristics)
Zhang  et  al.  (2014)/Leukemia  1
Local/Extensive  surgery  Lustig  et  al.  (2003)/CNS
Ahmet  et  al.  (2006)/CNS
2
Deﬁciency  of  growth  hormone  (GH)  Lustig  et  al.  (2003)/CNS
Ahmet  et  al.  (2006)/CNS
2
Reduced  energy  expenditure Harz  et  al.  (2003)/CNS  1
Functional capacity  compromised
(reduced  mobility  and/or  muscle
weakness)
Ness  et  al.  (2014)/CNS
Pietilä  et  al.  (2009)/CNS
Hoffman  et  al.  (2008)/Sarcoma
3
Watch television Miller  et  al.  (2010)/Leukemia  and  Lymphoma 1
Inadequate  nutrition Berdan  et  al.  (2014)/All  types
Shams-White  et  al.  (2015)/Leukemia  and  lymphoma
2
Metabolic  syndrome  No.  of  studies
Risk  factor Author/Type  of  tumor
HSCT  (including  total  body
irradiation  [TBI])
Van  Waas  M  et  al.  (2010)/Leukemia  and  CNS
Oudin  et  al.  (2011)/Leukemia
Taskinen  et  al.  (2000)/All  types
Frisk  et  al.  (2011)/All  types
Scott  Baker  et  al.  (2007)/All  types
5
n, number of studies evaluated.
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vparticipants,  type  of  tumor,  aim  of  the  study,  and  results
obtained.  Below  is  a  summary  of  major  studies  that  will  be
addressed  and  described  in  this  review  (Table  1).
It  was  decided  to  divide  the  discussion  topics  according
to  the  tumor  and  treatment  because  they  are  the  main  types
described  in  the  literature  correlated  with  obesity.
Results and  discussion
Acute  lymphoblastic  leukemia  (ALL)Acute  lymphoblastic  leukemia  (ALL)  is  the  most  common
malignant  childhood  cancer  and  it  has  been  considered  an
important  model  for  the  study  of  metabolic  disorders  and
w
o
t
fheir  correlation  with  cardiovascular  events,  such  as  strokes
nd  chronic  health  conditions  among  survivors  of  ALL.6
Excessive  weight  gain  occurring  during  treatment  for  ALL
s  usually  related  to  the  use  of  steroids,  appetite  regula-
ion  disorders,  radiotherapy  to  the  central  nervous  system
CNS),  and  reduced  energy  expenditure  due  to  physical
nactivity.3 Post-treatment  weight  gain  conditions  have  also
een  associated  with  CRT,  and  women  are  more  affected
han  men  according  to  an  analysis  of  1765  adult  survivors
f  childhood  cancer  enrolled  in  the  Childhood  Cancer  Sur-
ivor  Study  (CCSS).  Among  these,  female  survivors  treated
ith  20  Gy  had  a  two-to-three  times  greater  probability
f  being  obese  compared  to  their  male  siblings.  Those
reated  before  the  age  of  ﬁve  years  old  were  almost
our  times  more  likely  to  be  obese  than  their  siblings.  In
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ddition,  boys  treated  with  20  Gy  had  an  almost  two  times
ncreased  chance  of  being  obese  compared  to  their  male
iblings.7,8
In  agreement  with  this  observed  inﬂuence  of  radiothe-
apy  on  weight,  Mayer  et  al.  report  that  the  prevalence  of
besity  was  signiﬁcantly  higher  after  ALL  therapy  when  the
actors  of  ALL  post-therapy  obesity  were  evaluated  during  a
ransversal  study  with  39  survivors  of  the  disease.  In  compar-
son  with  non-irradiated  patients,  those  who  had  undergone
herapy  had  highly  reduced  basal  metabolic  rates  (BMR)  as
ell  as  a  reduction  in  their  physical  activity  levels,  and  lower
oncentrations  of  insulin-like  growth  factor  binding  protein
 and  free  thyroxin.9
In  its  analysis  of  the  differential  effects  of  CRT,  spinal
adiotherapy,  and  total  body  irradiation  (TBI)  on  growth  and
ndocrine  function  in  3467  ALL  survivors,  the  CCSS  found
hat  patients  treated  with  TBI  were  signiﬁcantly  more  likely
o  report  themselves  as  underweight  than  those  who  had  not
eceived  any  dose  of  radiotherapy.  It  was  also  found  that
hose  treated  with  CRT  were  signiﬁcantly  more  likely  to  be
verweight  or  obese.  The  study  showed  that  age  <10  years
t  diagnosis  and  HSCT  are  independent  characteristics  asso-
iated  with  BMI  alterations  and  an  increased  risk  of  being
verweight  or  obese.  Other  ﬁndings  from  the  study  include
he  following:  supplementation  with  growth  hormone  (GH)
as  associated  with  being  underweight,  and  female  sur-
ivors,  contrary  to  previous  studies,  were  less  likely  to
e  overweight  or  obese  than  male  survivors.  The  authors
oncluded  that  patients  treated  with  any  of  the  aforemen-
ioned  therapies  had  an  increased  risk  of  alterations  in  body
omposition.10
Despite  ample  evidence  for  the  association  between  obe-
ity  and  RT,  studies  have  also  shown  that  patients  present  a
isk  of  becoming  overweight  during  all  phases  of  treatment,
egardless  of  the  treatment  modality.  When  the  BMI  of  183
LL  patients  was  evaluated  during  all  phases  of  treatment
diagnosis,  induction,  consolidation,  and  maintenance),  it
as  been  observed  that,  at  diagnosis,  36%  of  the  patients
ere  overweight  and  19%  were  obese.  The  median  BMI  z-
core  increased  during  the  induction  phase  and  then  later
eturned  to  base  line;  however,  it  increased  again  through-
ut  the  ﬁrst  22  months  of  maintenance.  By  the  end  of  the
reatment,  49%  of  the  patients  were  overweight  and  21%
ere  obese.  The  increase  in  the  BMI  z-score  during  the  diag-
osis  was  associated  with  the  z-score  increase  during  the
aintenance  phase.  The  study  concluded  that  patients  are
t  risk  of  an  elevation  in  BMI  at  all  phases  of  treatment,
hich  places  them  at  greater  risk  for  adverse  health  condi-
ions  in  their  future.11
Another  similar  study  examined  the  BMI  of  83  pediatric
urvivors  of  ALL  and  observed  that  weight  at  diagnosis  and
MI  z-score  were  two  important  predictors  of  overweight
nd  obesity  at  the  end  of  the  treatment.  Patients  who  were
verweight  or  obese  at  diagnosis  were  11.9  times  more
ikely  to  be  overweight  or  obese  by  the  end  of  their  treat-
ent  than  those  who  were  underweight  or  normal  weight
t  diagnosis.  An  increase  of  one  unit  in  the  BMI  z-score
t  diagnosis  was  associated  with  a  tripling  in  the  risk  of
eing  overweight  or  obese  by  the  end  of  the  treatment.
he  study  ﬁnally  concludes  that  ALL  survivors  are  at  risk  of
ecoming  overweight  at  the  beginning  of  treatment  and  that
heir  weight  increase  is  maintained  throughout  treatment,
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aking  early  intervention  necessary.12 Reafﬁrming  these
ndings,  the  same  author  found  in  a  meta-analysis  of  ALL
urvivors  that  obesity  is  prevalent  in  this  group  and  is  inde-
endent  of  patient  characteristics  such  as  sex  or  age  at
iagnosis,  and  treatments,  such  as  cranial  irradiation.  Thus,
ealth  professionals  may  need  to  pay  special  attention  to
hese  survivors.13
Besides  obesity,  metabolic  syndrome  (MetS)  is  also  expe-
ienced  by  childhood  cancer  survivors  as  a consequence
f  anti-neoplastic  treatments.  MetS  can  be  deﬁned  as  a
roup  of  interrelated  risk  factors  of  metabolic  origin  that
ontribute  directly  to  the  development  of  cardiovascular
isease  (CVD)  and/or  diabetes  mellitus  type  2.  Well-known
isk  factors  for  MetS  include  atherogenic  dyslipidemia,  high
lood  pressure,  and  high  plasmatic  glucose  levels.  Indi-
iduals  with  these  characteristics  commonly  present  with
 pro-thrombosis  and  pro-inﬂammatory  state.  Atherogenic
yslipidemia  comprises  a  series  of  alterations  in  levels  of
ipoproteins,  including  a  rise  in  triacylglycerol,  apolipopro-
ein  B (apo  B),  and  low-density  lipoprotein  (LDL),  and  a
ecrease  in  high-density  lipoprotein  (HDL).  Abdominal  obe-
ity,  insulin  resistance  (IR),  physical  inactivity,  aging,  and
ormonal  imbalance  can  promote  metabolic  risk  factors.14
Childhood  cancer  survivors,  especially  those  treated  with
ranial  irradiation,  face  a  higher  risk  of  developing  MetS  as
dults,15 particularly  those  who  had  ALL  and  CNS  cancers
nd  presented  with  risk  factors  such  as  visceral  adiposity,
yslipidemia,  IR,  and  hypertension.16,17 The  authors  of  one
tudy  determined  that  the  prevalence  of  MetS  in  French  ALL
urvivors  was  9.2%,  which  was  double  the  rate  in  the  general
opulation  of  French  young  adults.  There  was  no  association
ound  between  the  prevalence  of  MetS  and  gender,  age  at
iagnosis,  leukemia  subtype,  or  treatment  with  steroids  or
NS  radiation.18
Endocrine  disorders  observed  in  survivors  who  received
n  HSCT  are  multifactorial  and  are  correlated  to  the  age
f  the  patient,  base  disease,  and  type  of  transplant  (autol-
gous  or  allogeneic).  The  HSCT  conditioning  regimen  that
ses  high  doses  of  chemotherapy  agents  alone  or  in  combina-
ion  with  radiotherapy,  which  is  intended  to  eliminate  active
nd  residual  malignant  cells,  may  be  a  contributing  factor  in
he  development  of  endocrine  disorders.  Another  contribut-
ng  factor  could  be  administration  of  immunosuppressive
gents,  which  can  produce  either  early  or  late  hematopoi-
tic  toxicity,  as  prophylaxis  against  graft-versus-host  disease
GVHD).19,20
entral  nervous  system
ormonal  deﬁciencies  and  obesity  are  common
omplications  after  treatment  of  CNS  tumors.  Currently,
he  main  risk  factors  that  seem  to  predict  the  development
f  obesity  in  survivors  of  CNS  tumors  are  age  at  diagnosis,
rradiation  of  the  hypothalamus  greater  than  51  Gy,  location
f  the  tumor,  extensiveness  of  the  surgery,  histology  of  the
umor,  and  the  presence  of  endocrine  diseases,  particularly
H  deﬁciency.21,22Craniopharyngiomas  are  rare  tumors  accounting  for
%--5%  of  CNS  tumors  and  originate  from  remnants  of
he  squamous  epithelium  of  Rathke’s  pouch.23 Survivors  of
raniopharyngioma  have  a  substantially  increased  risk  of
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extreme  obesity  due  to  the  location  of  their  brain  tumor  and
the  hypothalamic  damage  resulting  from  surgical  resection.
These  individuals  experience  a  state  of  hypothalamic  obe-
sity,  deﬁned  as  any  damage  to  the  energy  control  centers
of  the  hypothalamus,  which  is  responsible  for  the  regu-
lation  of  body  weight  through  balancing  food  ingestion,
energy  expenditure,  and  amount  of  adipose  tissue.24 These
lesions,  which  may  be  present  on  the  ventromedial  hypothal-
amus,  paraventricular  nucleus,  arcuate  nucleus,  and  lateral
hypothalamus,  can  result  from  surgical  procedures,  anti-
neoplastic  treatments,  or  the  tumor  itself.  The  damage  may
be  structural,  functional,  or  genetic  in  nature,  and  ulti-
mately  compromises  hypothalamic  functions,  leading  to  a
state  of  severe  obesity.25
The  resulting  morbidity  from  radical  tumor  resection  per-
formed  to  reduce  the  chances  of  relapse  is  explained  by
the  intimate  anatomic  relation  of  craniopharyngiomas  with
the  neurohypophysis  and  particularly  with  the  hypothala-
mus.  Hypothalamic-hypophysis  disorder  ----  characterized  by
pan-hypopituitarism,  obesity,  hyperphagia,  obsession  with
the  pursuit  of  food,  and  neuropsychological  disorders  ----  dra-
matically  affects  the  quality  of  life  of  affected  children  and
their  families.26
Although  the  dose  and  the  duration  of  treatment  with
peri-surgical  dexamethasone  has  a  short-term  inﬂuence  on
post-surgical  weight  gain  of  craniopharyngioma  patients,  it
cannot  be  said  to  affect  long-term  morbid  obesity.  Other
factors  can  be  correlated  to  the  weight  gain  in  this  group,
as  observed  by  Harz  and  collaborators,  who  found  that  their
obese  craniopharyngioma  patients  had  nearly  normal  caloric
ingestion  but  reduced  energy  expenditure  in  comparison  to
the  control  group  with  a  similar  BMI.  The  authors  hypothe-
size  that  this  phenomenon  may  be  related  to  neurological
and  visual  deﬁcits,  as  well  as  to  an  uncontrolled  production
of  melatonin  leading  to  an  increase  in  daytime  sleepiness.27
Treatments  have  been  proposed  to  minimize  the  hypo-
thalamic  obesity  present  in  this  group  of  patients.  In  a
double-blind  randomized  controlled  study  using  octreotide
therapy  for  pediatric  hypothalamic  obesity,  it  was  observed
that,  analogous  to  somatostatin,  it  resulted  in  stabilization
of  weight  and  BMI.  Furthermore,  the  placebo  treatment
did  not  result  in  any  alteration  in  weight  gain  index,  sug-
gesting  beneﬁcial  effects  of  octreotide  in  this  group.28
Another  study  evaluated  the  effect  of  combined  therapy
with  diazoxide-metformin  for  hypothalamic  obesity,  and
observed  a  reduction  in  BMI  and  area  under  the  insulin  curve,
which  is  a  predictor  of  the  efﬁcacy  of  the  treatment.29
Besides  medicinal  therapies,  gastric  bypass  has  been  pro-
posed  as  an  efﬁcient  and  safe  method  to  treat  hypothalamic
obesity,  as  it  has  been  described  in  a  case  study  of  an  adult
man  who  had  undergone  craniopharyngioma  resection  at  the
age  of  eight.  Eighteen  months  after  the  bypass  there  was  a
reduction  in  BMI  from  52  kg/m  to  31.9  kg/m,  as  well  as  full
remission  of  type  2  diabetes  and  express  improvement  of  his
apnea.30
Other  CNS  tumor  types  can  also  affect  metabolism  in
an  important  way.  Heikens  et  al.  investigated  risk  factors
for  CDV  in  a  mixed  group  of  long-term  survivors  of  CNS
tumors  and  described  an  altered  risk  proﬁle  for  this  group
of  patients  due  to  dyslipidemia,  central  obesity,  and  ele-
vated  systolic  blood  pressure,  especially  for  those  suffering
from  a  GH  deﬁciency.31 Additional  mechanisms  contribute  to
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xcess  weight  in  this  group,  including  reduced  mobility,  mus-
le  weakness,  and  reduced  tolerance  for  physical  activity,
ompromising  their  ability  to  fully  participate  in  a  normal
aily  routine.32,33
ther  types  of  cancer
xcess  weight  has  not  only  been  demonstrated  in  survivors  of
LL  or  CNS  tumors.  Other  studies  exploring  isolated  groups
f  tumor  types,  in  addition  to  grouped  studies  on  survivors  of
hildhood  cancer,  have  shown  changes  in  the  BMI  patterns
f  survivors.
When  analyzing  survivors  of  childhood  sarcoma  ---- pre-
ominantly  Ewing  sarcoma  ----  in  the  United  States,  survivors
ere  more  likely  to  have  two  or  more  criteria  for  MetS
hen  compared  with  their  controls.  An  analysis  of  individual
etS  criteria  revealed  a  greater  prevalence  of  hyperten-
ion  and  hypertriglyceridemia.  Regarding  nutritional  status
ased  on  the  BMI,  22%  of  survivors  were  obese  and  28%  were
verweight.  Both  male  and  female  survivors  had  increased
otal  body  fat  as  measured  by  dual-energy  X-ray  absorp-
iometry  (DEXA).  Other  parameters,  such  as  testosterone
evels  and  physical  activity,  were  also  assessed,  revealing
hat  among  male  survivors,  total  testosterone  was  reduced.
n  addition,  free  testosterone  and  mean  activity  z-scores
ad  a  strong  tendency  to  decline  as  the  number  of  MetS
ndicators  increased.  The  authors  concluded  that  this  group
f  patients  had  an  increase  in  the  prevalence  of  MetS,
specially  among  those  younger  than  40  years  of  age.
he  development  of  MetS  in  this  population  was  associ-
ted  with  reduced  levels  of  testosterone  and  functional
apacity.34
Both  changes  in  body  composition  of  survivors  and  issues
elated  to  the  use  of  BMI  have  been  described.  A  study  of
70  ALL  and  lymphoma  survivors  sought  to  compare  body
at  indicators  and  metabolic  factors  associated  with  body
at,  and  to  determine  the  risk  of  adiposity  in  survivors  of
hildhood  cancer  who  had  received  a  diverse  range  of  treat-
ents.  The  authors  concluded  that  total  body  and  abdominal
at  are  higher  in  male  survivors  of  pediatric  cancer  than
n  sibling  controls,  and  that  BMI  is  not  a  sensitive  indica-
or  of  adiposity.  For  both  male  and  female  survivors,  CRT
nd  the  habit  of  watching  television  were  associated  with
diposity.35
Cancer  treatments  may  have  an  impact  on  the
ypothalamic-pituitary  brain  region,  causing  long-term
hanges  in  consumption  and  binge  eating,  as  suggested
y  authors  using  a  modiﬁed  version  of  the  Food  Craving
nventory  in  22  survivors  of  pediatric  leukemia  and  lym-
homa.  Compared  to  survivors  diagnosed  at  a  younger  age
<4.5  years),  those  diagnosed  at  an  older  age  had  signiﬁ-
antly  greater  total  cravings  and  cravings  for  fast-foods,
weets,  carbohydrates,  and  fat;  therefore,  age  at  diagno-
is  may  potentially  affect  food  cravings  in  childhood  cancer
urvivors.36
Healthier  habits,  such  as  adequate  nutrition,  a  modiﬁ-
ble  and  preventive  factor  of  chronic  diseases,  have  not
een  demonstrated  in  survivors,  as  pointed  out  in  a  study  by
erdan  and  collaborators  in  2014  that  aimed  to  assess  the
dherence  of  childhood  cancer  survivors  to  the  guidelines
f  the  American  Cancer  Society  (ACS)  in  comparison  with  a
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ontrol  group.  Only  35.8%  of  the  surviving  patients  fell  within
 healthy  BMI  range,  while  2.9%  were  underweight,  28.9%
ere  overweight,  and  32.4%  were  classiﬁed  as  obese.  His-
anic  survivors  had  a  higher  BMI  than  Caucasians.  In  regards
o  food  consumption,  only  4.8%  of  survivors  fully  adhered
o  the  recommendations  of  the  ACS.  Only  10.2%  complied
ith  the  recommended  intake  of  dietary  ﬁber  and  17.7%
onsumed  ﬁve  fruits  and  vegetables  per  day,  while  46.2%
et  the  recommendation  for  processed  red  meat.37
ematopoietic  stem-cell  transplant  (HSCT)
SCT,  including  autologous  and  allogeneic  stem  cell  trans-
lants  from  bone  marrow,  peripheral  blood,  and  umbilical
ord  blood,  has  increased  considerably  in  recent  years.
SCT  is  applied  mainly  in  the  treatment  of  leukemia  and
olid  tumors,  but  it  is  also  effective  in  the  treatment
f  hematological,  immunological,  and  genetic  disorders,
nd  in  the  cure  of  non-hematological  metabolic  diseases.
dvances  in  transplant  technology  and  treatment  support
ractices  have  led  to  progressive  improvements  in  the  sur-
ival  of  HSCT  recipients;  however,  due  to  patients  living
onger  after  the  transplant,  the  risk  of  developing  late
omplications  related  to  pre-,  peri-,  and  post-transplant
xposures  has  increased.  These  complications  may  cause
ubstantial  morbidity,  worsen  patients’  quality  of  life,  and
ontribute  to  late  mortality  in  these  individuals.  The  most
ommon  adverse  effects,  which  generally  result  from  pre-
ransplant  conditioning  regimes,  include  growth  and  thyroid
isorders,  metabolic  changes,  gonadal  insufﬁciency,  and
steoporosis.4,38
When  the  frequency  of  late  effects  on  glucose  and  lipid
etabolism  after  childhood  transplantation  was  evaluated,
2%  of  the  patients  with  transplants  were  observed  to  have
R.  The  main  indicators  of  MetS  (combined  hyperinsulinemia
nd  hypertriglyceridemia)  were  found  in  39%  of  transplant
atients,  compared  to  8%  in  a  control  group  of  ALL  sur-
ivors  treated  only  with  chemotherapy  (no  HSCT)  and  0%
n  healthy  controls.  The  frequency  of  IR  increased  with  time
fter  the  HSCT  was  performed.  Abdominal  obesity  was  com-
on  among  patients  with  IR.  The  authors  concluded  that
ong-term  survivors  who  have  undergone  HSCT  are  at  sub-
tantial  risk  of  IR,  glucose  intolerance,  and  type  2  diabetes
ellitus,  even  with  normal  weight  and  at  a  young  age.39
he  authors  suggest  that  the  decrease  in  insulin  sensitiv-
ty  can  be  explained  by  adverse  body  composition  after
SCT,  as  assessed  in  a  cross-sectional  study  of  18  survivors
f  blood  cancer  (leukemia  and  lymphoma)  in  childhood  who
nderwent  transplantation  and  completed  10  years  without
reatment.  Using  DEXA,  it  was  shown  that  fat  mass  was  sig-
iﬁcantly  higher  and  lean  body  mass  signiﬁcantly  lower  in
he  survivors  than  in  control  patients,  and  these  parame-
ers  correlated  inversely  with  insulin  sensitivity.  The  median
MI  of  the  survivors  was  21.6  kg/m2.  BMI  tended  to  be  lower
n  the  survivor  group  due  to  reduced  lean  body  mass,  but
heir  higher  percentages  of  fat  mass  were  associated  with  a
ecrease  in  insulin  sensitivity.40
In  addition  to  the  HSCT  itself,  TBI  as  a  preparative  ther-
py  for  HSCT  has  been  described  as  playing  an  essential  role
n  the  genesis  of  IR,  as  was  pointed  out  by  a  large  multicenter
tudy  that  included  adult  and  pediatric  survivors  of  trans-
lantation.  The  risk  of  developing  type  2  diabetes  mellitus
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as  three  times  higher  in  patients  who  underwent  HSCT,  and
his  risk  was  associated  with  TBI.41
Although  endocrine  complications  in  patients  who  have
eceived  a  HSCT  have  been  well-described  in  the  literature,
he  causes  of  excess  weight  in  this  group  have  remained
ontroversial.  Such  controversy  possibly  exists  due  to  the
ompromised  speciﬁcity  of  using  BMI  as  a  marker  of  MetS
n  childhood  cancer  survivors,  especially  in  those  who  have
ndergone  transplantation.  One  study  measured  longitudi-
al  weight  and  body  composition  changes  in  survivors  of
alignant  hematologic  diseases  in  childhood  and  observed
 signiﬁcant  decrease  in  BMI  in  survivors  after  HSCT,  mainly
ue  to  a reduction  in  lean  body  mass.  According  to  the
uthors,  the  ﬁndings  of  the  study  may  be  attributable  to
BI  and/or  the  degree  of  chronic  GHVD.  Furthermore,  they
uggest  that  health  professionals  should  be  alert  to  losses
n  not  only  BMI,  but  also  in  lean  mass  in  these  survivors  in
rder  to  ensure  early  and  appropriate  intervention  based  on
utritional  education  and  physical  activity.42
Corroborating  these  ﬁndings,  Rubles  and  collaborators
bserved  that  54%  of  the  survivors  had  body  fat  percentages
measured  by  DEXA)  that  exceeded  the  recommendations
or  a  healthy  body  composition,  and  31%  qualiﬁed  as  having
entral  obesity.  Previous  treatment  with  TBI  was  associated
ith  a  greater  percentage  of  body  fat  and  central  obesity,
nd  GHVD  was  associated  with  a lower  percentage  of  body
at.  The  BMI  criteria  did  not  correctly  identify  the  HSCT  sur-
ivors  with  a  high  body  fat  percentage.  The  study  concluded
hat  survivors  who  received  a  HSCT  in  childhood  are  at  risk
f  obesity  and  central  obesity,  which  is  not  easily  identiﬁed
y  the  standard  BMI  criteria.43
onclusion
urvivors  of  ALL  and  CNS  tumors  are  more  prone  to  devel-
ping  obesity  due  to  the  employed  treatment  modalities,
ut  antineoplastic  treatments  inﬂuence  the  appearance  of
xcess  weight  in  all  survivors  of  childhood  cancer,  regardless
f  tumor  type.  As  in  the  general  population,  other  factors
ontribute  to  weight  gain  in  survivors,  given  that  obesity  is  a
ulti-factorial  disease;  these  factors  include  poor  nutrition,
hysical  inactivity,  and  individual  genetic  characteristics.  In
ddition,  the  administration  of  HSCT  and  TBI  affect  body
omposition  by  increasing  adiposity,  reducing  lean  body
ass,  and  increasing  metabolic  complications.  Clearly  there
s  need  for  assistance  in  this  group.  Strategies  for  early
dentiﬁcation  of  high-risk  patients  and  development  of  inter-
entional  models,  including  nutritional  counseling,  should
e  offered  by  health  professionals  in  order  to  minimize
nd/or  prevent  this  chronic  complication  of  antineoplastic
herapy.
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